Efficacy and Tolerability of Amlodipine Camsylate/Losartan 5/100-mg Versus Losartan/Hydrochlorothiazide 100/12.5-mg Fixed-Dose Combination in Hypertensive Patients Nonresponsive to Losartan 100-mg Monotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Suh, Soon Yong | - |
dc.contributor.author | Ahn, Taehoon | - |
dc.contributor.author | Bae, Jang-Ho | - |
dc.contributor.author | Lim, Do-Sun | - |
dc.contributor.author | Lee, Seoung Uk | - |
dc.contributor.author | Kim, Young Kwon | - |
dc.contributor.author | Hyon, Min Su | - |
dc.contributor.author | Kim, Won Ho | - |
dc.contributor.author | Han, Kyoo Rok | - |
dc.contributor.author | Park, Hoon Ki | - |
dc.date.accessioned | 2021-09-05T04:53:23Z | - |
dc.date.available | 2021-09-05T04:53:23Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2014-10 | - |
dc.identifier.issn | 0149-2918 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/97325 | - |
dc.description.abstract | Purpose: The aim of this study was to determine whether the efficacy and tolerability of amlodipine camsylate/losartan 5/100 mg/d (AML/LOS) are noninferior to those of losartan/hydrochlorothiazide 100/12.5 mg/d (LOS/HCTZ) fixed-dose combination in hypertensive patients unresponsive to losartan 100-mg/d monotherapy. Methods: Male and female patients aged >= 18 years with hypertension despite 4-week, stable treatment with losartan 100-mg/d monotherapy were eligible for inclusion in this multicenter, randomized, double-blind study. Patients were randomly assigned to receive AML/LOS or LOS/HCTZ once daily for 8 weeks. The primary end point was the change from baseline to week 8 in sitting diastolic blood pressure (Delta siDBP), and the secondary end points were the changes from baseline to 4 weeks in siDBP and sitting systolic BP (Delta siSBP) and changes from baseline to 4 and 8 weeks in BP response rate. Tolerability was evaluated by physical examination, including vital sign measurement; laboratory analysis; and ECG. Findings: Of 275 patients screened at 9 cardiovascular centers, 199 were enrolled (AML/LOS, n = 101; LOS/HCTZ, n = 98), and 183 completed the study. The demographic characteristics were similar between the 2 groups (mean age, 51.56 [9.97] years; men, 70.53%). At 8 weeks, the mean Delta siDBP values were -11.54 (7.89) and -9.05 (6.57) mm Hg in the AML/LOS and LOS/HCTZ groups, respectively (both, P < 0.0001 vs baseline). The mean difference between the 2 groups was -2.57 mm Hg, a nonsignificant difference, meaning that AML/LOS was noninferior to LOS/HCTZ with regard to the primary end point. At 8 weeks, the mean uric acid level was changed significantly from baseline in the LOS/HCTZ group (+0.41 [0.80] mg/dL; P < 0.0001) but not in the AML/LOS group (-0.12 [0.82] mg/dL), representing a significant intergroup difference (P < 0.0001). Nineteen patients each in the AML/LOS (18.81%) and LOS/HCTZ (20.00%) groups experienced >= 1 adverse event, with 4 (3.96%) and 3 (3.16%) patients, respectively, experiencing 1 or more events considered by the investigators to have been treatment related. (C) 2014 Elsevier HS Journals, Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | SERUM URIC-ACID | - |
dc.subject | CARDIOVASCULAR EVENTS | - |
dc.subject | OPEN-LABEL | - |
dc.subject | RISK | - |
dc.subject | ANTAGONIST | - |
dc.subject | PREVENTION | - |
dc.subject | OUTCOMES | - |
dc.subject | THERAPY | - |
dc.subject | TRIAL | - |
dc.title | Efficacy and Tolerability of Amlodipine Camsylate/Losartan 5/100-mg Versus Losartan/Hydrochlorothiazide 100/12.5-mg Fixed-Dose Combination in Hypertensive Patients Nonresponsive to Losartan 100-mg Monotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lim, Do-Sun | - |
dc.identifier.doi | 10.1016/j.clinthera.2014.07.003 | - |
dc.identifier.scopusid | 2-s2.0-84908263014 | - |
dc.identifier.wosid | 000344426500012 | - |
dc.identifier.bibliographicCitation | CLINICAL THERAPEUTICS, v.36, no.10, pp.1402 - 1411 | - |
dc.relation.isPartOf | CLINICAL THERAPEUTICS | - |
dc.citation.title | CLINICAL THERAPEUTICS | - |
dc.citation.volume | 36 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1402 | - |
dc.citation.endPage | 1411 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | SERUM URIC-ACID | - |
dc.subject.keywordPlus | CARDIOVASCULAR EVENTS | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordPlus | ANTAGONIST | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | hypertension | - |
dc.subject.keywordAuthor | losartan | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.